IRIDEX CORP

IRIDEX Corporation (Nasdaq: IRIDEX) is an ophthalmic medical technology company focused on developing and commercializing breakthrough products and procedures for treating sight-threatening eye conditions, particularly glaucoma and retinal diseases. The company operates through a comprehensive product portfolio consisting of laser consoles, delivery devices, and consumable probes designed to provide physicians with innovative treatment options that minimize tissue damage while maximizing clinical efficacy.

The company's proprietary MicroPulse Technology and Endpoint Management Technology represent core competitive advantages. MicroPulse technology delivers short, microsecond-long laser pulses that allow tissue to cool between pulses, enabling low-energy, subvisible, tissue-sparing therapy with superior safety profiles compared to standard continuous-wave laser treatment. Endpoint Management technology uses a proprietary delivery algorithm to titrate laser energy for precise therapeutic control. The company's laser console product lines include the Cyclo G6 for glaucoma treatment, the IQ 532 and IQ 577 portable systems for medical retina applications, the PASCAL system offering pattern scanning capabilities, and the OcuLight TX and OcuLight SLx systems for surgical retina procedures. Consumable products include the MicroPulse P3 probe, G-Probe and G-Probe Illuminate delivery devices, and EndoProbe handpieces.

IRIDEX generates recurring revenues through both capital equipment sales and consumable products, with single-use laser probes and service contracts providing steady revenue streams. The company maintains a direct sales force in the United States and Germany while leveraging Topcon Corporation and independent distributors for international markets. In fiscal year 2025, international sales represented 55.9 percent of total revenues of $52.7 million.

The company employs approximately 11 research and development engineers and maintains manufacturing operations at its Mountain View, California facility, where it assembles critical subassemblies and final products while sourcing components from third-party suppliers. IRIDEX holds 67 active United States patents and 94 active international patents protecting its proprietary technologies. The company maintains ISO 13485:2016 certification and holds FDA 510(k) clearances for its product lines, with CE mark certification for European markets. More information is available at www.iridex.com.